Kenneth Laxer, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 13
Offices
13 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Sutter Delta Medical Center · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Laxer’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G28500 · Current
Licensed to practise in California · since 1974 · expires 2028-04-30 · University of California, Irvine College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Sutter Delta Medical CenterAntioch, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Sutter Delta Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.03) · 561 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.47 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 176.46 (114.75 to 238.17) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 260 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,274 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 3,285 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,374 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 364 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.49 to 3.83) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.63 (0 to 18.4) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.24 (0 to 1.07) · 2,713 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.962 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 116 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 316 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 20 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.1 · 298 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.3 · 269 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 283 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.7 to 17.1) · 529 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 45 cases | No different | Jan 2024 – Dec 2024 |
What patients said (610 patients answered, 13% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$41,578
Medicare paid this office $41,578 for 215 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 53 | $18,120 | $179 |
| Return visit (30+ min) | 59 | $9,858 | $100 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 33 | $3,121 | $89 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 20 | $2,459 | $117 |
| Long return visit (40+ min) | 12 | $1,959 | $151 |
See all 9 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 53 | $18,120 | $179 |
| Return visit (30+ min) | 59 | $9,858 | $100 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 33 | $3,121 | $89 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 20 | $2,459 | $117 |
| Long return visit (40+ min) | 12 | $1,959 | $151 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 18 | $1,509 | $75 |
| Measurement of brain wave activity (eeg), awake and drowsy | 28 | $1,292 | $46 |
| Short return visit (20+ min) | 13 | $931 | $66 |
| Measurement of brain wave activity (eeg), awake and asleep | 12 | $496 | $41 |
Who their Medicare patients are
215 Original Medicare patients in 2024. Average age 70 · Under 65 26% · 85 and older 12% · Women 47% · Also on Medicaid 52% · Health risk score 2.05. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 72% · Stroke 40% · Depression 39% · Diabetes 37% · Chronic kidney disease 32% · Coronary heart disease 31% · Dementia 27% · Heart failure 21% · Atrial fibrillation 20% · COPD 17% · Cancer 16%.
The office billed $205,827, Medicare allowed $56,167 and paid $41,578; for 362 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 215 | 362 | 70 | 2.05 | $205,827 | $41,578 |
| 2023 | 183 | 329 | 70 | 2.01 | $176,377 | $40,169 |
| 2022 | 160 | 315 | 68 | 1.60 | $144,350 | $35,038 |
| 2021 | 226 | 392 | 69 | 1.99 | $171,980 | $42,493 |
| 2020 | 214 | 369 | 69 | 2.08 | $199,517 | $44,113 |
| 2019 | 168 | 288 | 68 | 1.88 | $181,682 | $37,894 |
| 2018 | 245 | 382 | 68 | 1.99 | $230,129 | $47,465 |
| 2017 | 275 | 430 | 69 | 2.00 | $267,243 | $57,374 |
| 2016 | 315 | 513 | 71 | 2.01 | $333,746 | $71,082 |
| 2015 | 190 | 334 | 69 | 2.02 | $212,043 | $46,226 |
| 2014 | 155 | 258 | 67 | 1.84 | $172,739 | $37,553 |
| 2013 | 159 | 263 | 68 | 1.79 | $147,746 | $31,403 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 50 | $17,880 | $186 |
| Return visit (30+ min) | 59 | $12,144 | $109 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 19 | $2,248 | $118 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 14 | $1,268 | $91 |
| Measurement of brain wave activity (eeg), awake and asleep | 21 | $1,086 | $49 |
| Measurement of brain wave activity (eeg), awake and drowsy | 16 | $832 | $49 |
2022: 5 services
| Return visit (30+ min) | 67 | $13,500 | $101 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 31 | $12,749 | $187 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 16 | $2,187 | $121 |
| Measurement of brain wave activity (eeg), awake and asleep | 27 | $1,351 | $50 |
| Measurement of brain wave activity (eeg), awake and drowsy | 15 | $775 | $52 |
2021: 7 services
| Return visit (30+ min) | 71 | $15,051 | $102 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 48 | $13,815 | $189 |
| Measurement of brain wave activity (eeg), awake and drowsy | 52 | $2,690 | $51 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 19 | $2,323 | $122 |
| Long return visit (40+ min) | 17 | $2,150 | $119 |
| New patient visit (60+ min) | 11 | $2,132 | $194 |
| Measurement of brain wave activity (eeg), awake and asleep | 39 | $1,883 | $48 |
2020: 7 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 57 | $20,947 | $192 |
| Return visit (30+ min) | 50 | $6,781 | $78 |
| Long return visit (40+ min) | 26 | $3,175 | $122 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 19 | $2,475 | $124 |
| Measurement of brain wave activity (eeg), awake and drowsy | 45 | $2,358 | $51 |
| Measurement of brain wave activity (eeg), awake and asleep | 37 | $1,885 | $51 |
| Extended office or other outpatient service, first hour | 12 | $1,431 | $119 |
2019: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 45 | $23,456 | $297 |
| Return visit (30+ min) | 47 | $8,799 | $86 |
| Measurement of brain wave activity (eeg), awake and drowsy | 42 | $2,161 | $51 |
| Measurement of brain wave activity (eeg), awake and asleep | 30 | $1,498 | $50 |
2018: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 50 | $27,911 | $291 |
| Return visit (30+ min) | 55 | $9,728 | $83 |
| Measurement of brain wave activity (eeg), awake and asleep | 77 | $3,794 | $48 |
| Measurement of brain wave activity (eeg), awake and drowsy | 65 | $3,271 | $48 |
2017: 5 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 64 | $34,184 | $292 |
| Return visit (30+ min) | 57 | $10,546 | $87 |
| Measurement of brain wave activity (eeg), awake and asleep | 80 | $4,052 | $49 |
| Measurement of brain wave activity (eeg), awake and drowsy | 69 | $3,600 | $50 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 12 | $947 | $79 |
2016: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 89 | $44,097 | $294 |
| Return visit (30+ min) | 55 | $12,006 | $81 |
| Measurement of brain wave activity (eeg), awake and asleep | 104 | $5,235 | $48 |
| Measurement of brain wave activity (eeg), awake and drowsy | 69 | $3,527 | $50 |
2015: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 49 | $25,770 | $293 |
| Return visit (30+ min) | 52 | $10,298 | $89 |
| Measurement of brain wave activity (eeg), awake and asleep | 52 | $2,841 | $52 |
| Measurement of brain wave activity (eeg), awake and drowsy | 29 | $1,511 | $52 |
2014: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 40 | $24,188 | $295 |
| Return visit (30+ min) | 45 | $7,602 | $84 |
| Measurement of brain wave activity (eeg), awake and asleep | 47 | $2,464 | $52 |
| Measurement of brain wave activity (eeg), awake and drowsy | 19 | $1,000 | $53 |
2013: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 32 | $15,702 | $285 |
| Return visit (30+ min) | 41 | $7,458 | $82 |
| Measurement of brain wave activity (eeg), awake and asleep | 53 | $2,646 | $50 |
| Measurement of brain wave activity (eeg), awake and drowsy | 29 | $1,573 | $51 |
Medicaid work
$6,638 in 2024
Medicaid paid $6,638 for 22 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG) | 22 | $6,638 |
| 2024 | 22 | 1 | 12 | $6,638 |
| 2022 | 13 | 1 | 13 | $568 |
| 2020 | 13 | 1 | 13 | $228 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 13 | $568 |
2020
| Return visit (30+ min) | 13 | $228 |
Drugs they prescribed that Part D paid
$980,679
Pharmacies billed $980,679 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,311) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
793 generic and fewer than 11 brand-name prescriptions · $980,679 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xcopri | 207 | $294,188 | $1,421 |
| Fycompa | 122 | $168,914 | $1,385 |
| Briviact | 39 | $85,188 | $2,184 |
| Lamictal Xr | 39 | $61,327 | $1,572 |
| Vimpat | 24 | $57,285 | $2,387 |
See all 22 drugs
| Xcopri | 207 | $294,188 | $1,421 |
| Fycompa | 122 | $168,914 | $1,385 |
| Briviact | 39 | $85,188 | $2,184 |
| Lamictal Xr | 39 | $61,327 | $1,572 |
| Vimpat | 24 | $57,285 | $2,387 |
| Keppra | 22 | $52,637 | $2,393 |
| Lamotrigine Er | 97 | $50,144 | $517 |
| Keppra Xr | 14 | $23,231 | $1,659 |
| Clobazam | 154 | $18,296 | $119 |
| Lacosamide | 103 | $17,757 | $172 |
| Nayzilam | 17 | $11,109 | $653 |
| Levetiracetam | 139 | $8,177 | $59 |
| Carbamazepine Er | 17 | $4,976 | $293 |
| Dilantin | 12 | $2,968 | $247 |
| Levetiracetam Er | 21 | $2,555 | $122 |
| Lamotrigine | 106 | $2,072 | $20 |
| Divalproex Sodium Er | 21 | $1,314 | $63 |
| Oxcarbazepine | 12 | $1,004 | $84 |
| Zonisamide | 12 | $402 | $34 |
| Topiramate | 17 | $306 | $18 |
| Lorazepam | 41 | $160 | $4 |
| Fluoxetine | 12 | $57 | $5 |
Year by year
| 2024 | 1,311 | 99 | 0% (0) | None | $980,679 |
| 2023 | 1,343 | 98 | 0% (0) | None | $1,040,604 |
| 2022 | 1,439 | 112 | 0% (0) | None | $1,152,701 |
| 2021 | 1,312 | 101 | 0% (0) | 38% | $1,341,264 |
| 2020 | 1,009 | 85 | 0% (0) | 32% | $1,009,303 |
| 2019 | 954 | 61 | 0% (0) | 35% | $1,033,593 |
| 2018 | 935 | 68 | 0% (0) | None | $1,391,027 |
| 2017 | 1,036 | 73 | 0% (0) | None | $1,235,644 |
| 2016 | 1,010 | 68 | 0% (0) | None | $1,173,052 |
| 2015 | 1,084 | 71 | 0% (0) | None | $942,975 |
| 2014 | 1,057 | 60 | 0% (0) | None | $1,065,731 |
| 2013 | 1,070 | 60 | 0% (0) | None | $990,001 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Xcopri | 193 | $269,164 | $1,395 |
| Fycompa | 114 | $144,963 | $1,272 |
| Lamictal Xr | 42 | $126,613 | $3,015 |
| Vimpat | 40 | $94,745 | $2,369 |
| Briviact | 37 | $83,031 | $2,244 |
| Lamotrigine Er | 102 | $75,481 | $740 |
| Keppra | 18 | $38,126 | $2,118 |
| Clobazam | 151 | $27,656 | $183 |
| Lacosamide | 109 | $26,600 | $244 |
| Levetiracetam | 133 | $12,439 | $94 |
| Levetiracetam Er | 25 | $12,071 | $483 |
| Nayzilam | 17 | $11,545 | $679 |
| Lamotrigine | 123 | $4,818 | $39 |
| Dilantin | 13 | $3,693 | $284 |
| Divalproex Sodium Er | 17 | $2,747 | $162 |
| Topiramate | 30 | $1,240 | $41 |
| Zonisamide | 12 | $862 | $72 |
| Oxcarbazepine | 12 | $752 | $63 |
| Pregabalin | 12 | $657 | $55 |
| Lorazepam | 43 | $364 | $8 |
| Fluoxetine | 13 | $94 | $7 |
2022: 25 drugs
| Vimpat | 115 | $188,883 | $1,642 |
| Xcopri | 137 | $164,082 | $1,198 |
| Lamictal Xr | 37 | $151,297 | $4,089 |
| Fycompa | 99 | $138,720 | $1,401 |
| Briviact | 37 | $86,362 | $2,334 |
| Clobazam | 187 | $71,644 | $383 |
| Lamotrigine Er | 123 | $64,480 | $524 |
| Keppra | 17 | $44,859 | $2,639 |
| Lamictal | 19 | $43,883 | $2,310 |
| Lacosamide | 81 | $35,898 | $443 |
| Keppra Xr | 15 | $23,267 | $1,551 |
| Nayzilam | 18 | $11,298 | $628 |
| Levetiracetam Er | 17 | $10,574 | $622 |
| Levetiracetam | 138 | $8,399 | $61 |
| Lamotrigine | 150 | $4,717 | $31 |
| Dilantin | 17 | $4,004 | $236 |
| Divalproex Sodium Er | 14 | $2,492 | $178 |
| Divalproex | 16 | $1,920 | $120 |
| Oxcarbazepine | 14 | $1,453 | $104 |
| Pregabalin | 16 | $808 | $51 |
| Topiramate | 23 | $533 | $23 |
| Lorazepam | 38 | $280 | $7 |
| Omeprazole | 11 | $189 | $17 |
| Fluoxetine | 12 | $175 | $15 |
| Zonisamide | 12 | $150 | $13 |
2021: 19 drugs
| Vimpat | 207 | $338,145 | $1,634 |
| Lamictal Xr | 47 | $152,113 | $3,236 |
| Fycompa | 101 | $125,599 | $1,244 |
| Briviact | 44 | $84,862 | $1,929 |
| Xcopri | 47 | $59,602 | $1,268 |
| Lamotrigine Er | 113 | $55,224 | $489 |
| Clobazam | 208 | $44,428 | $214 |
| Levetiracetam | 150 | $9,763 | $65 |
| Carbamazepine Er | 11 | $7,552 | $687 |
| Lamotrigine | 104 | $3,533 | $34 |
| Divalproex Sodium Er | 12 | $3,127 | $261 |
| Dilantin | 14 | $2,574 | $184 |
| Divalproex | 25 | $1,628 | $65 |
| Oxcarbazepine | 17 | $1,313 | $77 |
| Zonisamide | 19 | $508 | $27 |
| Topiramate | 19 | $318 | $17 |
| Phenobarbital | 14 | $226 | $16 |
| Lorazepam | 21 | $187 | $9 |
| Omeprazole | 11 | $178 | $16 |
2020: 18 drugs
| Vimpat | 134 | $228,821 | $1,708 |
| Lamictal Xr | 39 | $125,331 | $3,214 |
| Fycompa | 61 | $65,797 | $1,079 |
| Briviact | 30 | $59,173 | $1,972 |
| Lamotrigine Er | 70 | $55,232 | $789 |
| Clobazam | 168 | $46,502 | $277 |
| Zonegran | 12 | $26,572 | $2,214 |
| Tegretol Xr | 16 | $8,345 | $522 |
| Levetiracetam | 108 | $6,006 | $56 |
| Lamotrigine | 113 | $4,053 | $36 |
| Dilantin | 23 | $3,686 | $160 |
| Pregabalin | 19 | $1,854 | $98 |
| Oxcarbazepine | 15 | $1,064 | $71 |
| Zonisamide | 18 | $760 | $42 |
| Phenobarbital | 12 | $252 | $21 |
| Divalproex | 15 | $210 | $14 |
| Lorazepam | 39 | $184 | $5 |
| Zolpidem | 11 | $48 | $4 |
2019: 23 drugs
| Vimpat | 137 | $203,435 | $1,485 |
| Lamictal Xr | 33 | $119,456 | $3,620 |
| Lamotrigine Er | 72 | $63,371 | $880 |
| Clobazam | 120 | $57,345 | $478 |
| Briviact | 31 | $52,444 | $1,692 |
| Lamictal | 13 | $51,304 | $3,946 |
| Fycompa | 38 | $50,121 | $1,319 |
| Onfi | 15 | $29,053 | $1,937 |
| Zonegran | 12 | $23,877 | $1,990 |
| Lyrica | 18 | $17,195 | $955 |
| Tegretol Xr | 11 | $7,378 | $671 |
| Lamotrigine | 109 | $3,800 | $35 |
| Levetiracetam | 68 | $3,791 | $56 |
| Levetiracetam Er | 16 | $3,551 | $222 |
| Dilantin | 24 | $3,409 | $142 |
| Divalproex Sodium Er | 13 | $1,634 | $126 |
| Oxcarbazepine | 12 | $585 | $49 |
| Zonisamide | 12 | $377 | $31 |
| Topiramate | 13 | $362 | $28 |
| Phenobarbital | 17 | $321 | $19 |
| Lorazepam | 49 | $245 | $5 |
| Zolpidem | 11 | $220 | $20 |
| Divalproex | 12 | $206 | $17 |
2018: 21 drugs
| Sabril | 23 | $516,963 | $22,477 |
| Onfi | 142 | $264,892 | $1,865 |
| Lamictal Xr | 35 | $148,499 | $4,243 |
| Vimpat | 89 | $137,539 | $1,545 |
| Briviact | 37 | $68,931 | $1,863 |
| Lamictal | 11 | $52,047 | $4,732 |
| Lamotrigine Er | 49 | $46,608 | $951 |
| Fycompa | 40 | $43,661 | $1,092 |
| Lyrica | 28 | $22,287 | $796 |
| Topamax | 13 | $14,323 | $1,102 |
| Clobazam | 12 | $11,621 | $968 |
| Levetiracetam | 106 | $6,080 | $57 |
| Lamotrigine | 121 | $3,054 | $25 |
| Dilantin | 16 | $2,202 | $138 |
| Oxcarbazepine | 12 | $625 | $52 |
| Topiramate | 15 | $291 | $19 |
| Lorazepam | 49 | $280 | $6 |
| Zonisamide | 14 | $250 | $18 |
| Zolpidem | 12 | $240 | $20 |
| Trazodone | 15 | $229 | $15 |
| Divalproex | 12 | $184 | $15 |
2017: 21 drugs
| Sabril | 23 | $471,503 | $20,500 |
| Onfi | 150 | $246,234 | $1,642 |
| Lamictal Xr | 36 | $122,337 | $3,398 |
| Vimpat | 88 | $120,999 | $1,375 |
| Lamotrigine Er | 65 | $65,576 | $1,009 |
| Briviact | 36 | $56,002 | $1,556 |
| Lamictal | 22 | $45,548 | $2,070 |
| Fycompa | 27 | $19,987 | $740 |
| Lyrica | 34 | $18,716 | $550 |
| Topamax | 12 | $12,152 | $1,013 |
| Tegretol Xr | 13 | $6,927 | $533 |
| Levetiracetam | 133 | $4,893 | $37 |
| Lamotrigine | 111 | $2,400 | $22 |
| Divalproex Sodium Er | 17 | $2,377 | $140 |
| Dilantin | 13 | $1,803 | $139 |
| Topiramate | 39 | $602 | $15 |
| Oxcarbazepine | 12 | $533 | $44 |
| Zonisamide | 24 | $507 | $21 |
| Lorazepam | 54 | $281 | $5 |
| Divalproex | 13 | $243 | $19 |
| Trazodone | 25 | $106 | $4 |
2016: 22 drugs
| Sabril | 26 | $507,030 | $19,501 |
| Vimpat | 123 | $157,097 | $1,277 |
| Onfi | 131 | $157,012 | $1,199 |
| Lamictal Xr | 33 | $116,638 | $3,534 |
| Lamotrigine Er | 51 | $59,941 | $1,175 |
| Lamictal | 12 | $33,970 | $2,831 |
| Keppra | 25 | $32,340 | $1,294 |
| Lyrica | 48 | $25,213 | $525 |
| Fycompa | 26 | $23,722 | $912 |
| Topamax | 11 | $10,300 | $936 |
| Felbamate | 15 | $8,896 | $593 |
| Tegretol Xr | 15 | $6,522 | $435 |
| Levetiracetam | 111 | $4,197 | $38 |
| Divalproex Sodium Er | 21 | $4,194 | $200 |
| Lamotrigine | 110 | $2,795 | $25 |
| Dilantin | 12 | $1,594 | $133 |
| Oxcarbazepine | 12 | $1,112 | $93 |
| Zonisamide | 23 | $710 | $31 |
| Topiramate | 38 | $695 | $18 |
| Divalproex | 12 | $269 | $22 |
| Lorazepam | 60 | $239 | $4 |
| Trazodone | 18 | $118 | $7 |
2015: 27 drugs
| Sabril | 24 | $343,449 | $14,310 |
| Vimpat | 130 | $162,688 | $1,251 |
| Onfi | 105 | $83,987 | $800 |
| Lamictal Xr | 31 | $79,317 | $2,559 |
| Keppra | 40 | $51,842 | $1,296 |
| Lamictal | 20 | $39,017 | $1,951 |
| Topamax | 23 | $36,464 | $1,585 |
| Fycompa | 31 | $29,326 | $946 |
| Lamotrigine Er | 21 | $19,177 | $913 |
| Felbamate | 19 | $18,398 | $968 |
| Lyrica | 40 | $17,535 | $438 |
| Tegretol Xr | 15 | $6,864 | $458 |
| Carbamazepine Er | 18 | $5,882 | $327 |
| Levetiracetam | 111 | $5,357 | $48 |
| Divalproex Sodium Er | 11 | $3,811 | $346 |
| Lamotrigine | 143 | $3,606 | $25 |
| Dilantin | 12 | $1,279 | $107 |
| Oxcarbazepine | 13 | $1,127 | $87 |
| Topiramate | 25 | $866 | $35 |
| Gabapentin | 14 | $704 | $50 |
| Zonisamide | 13 | $497 | $38 |
| Divalproex | 20 | $431 | $22 |
| Lorazepam | 50 | $344 | $7 |
| Clonazepam | 28 | $258 | $9 |
| Citalopram Hbr | 16 | $99 | $6 |
| Mirtazapine | 12 | $75 | $6 |
| Trazodone | 12 | $32 | $3 |
2014: 26 drugs
| Sabril | 46 | $554,787 | $12,061 |
| Vimpat | 120 | $160,673 | $1,339 |
| Lamictal Xr | 37 | $79,620 | $2,152 |
| Felbamate | 37 | $53,265 | $1,440 |
| Keppra | 30 | $43,685 | $1,456 |
| Topamax | 25 | $35,092 | $1,404 |
| Onfi | 69 | $31,757 | $460 |
| Lamotrigine Er | 28 | $20,676 | $738 |
| Lyrica | 40 | $14,557 | $364 |
| Levetiracetam | 110 | $6,890 | $63 |
| Fycompa | 11 | $6,423 | $584 |
| Tegretol Xr | 16 | $6,391 | $399 |
| Lamotrigine | 149 | $3,723 | $25 |
| Depakote | 12 | $3,564 | $297 |
| Gabapentin | 16 | $1,270 | $79 |
| Dilantin | 12 | $1,170 | $97 |
| Carbamazepine Er | 11 | $1,116 | $101 |
| Topiramate | 19 | $838 | $44 |
| Oxcarbazepine | 12 | $549 | $46 |
| Phenytoin Sodium Extended | 24 | $503 | $21 |
| Clonazepam | 34 | $347 | $10 |
| Divalproex | 15 | $334 | $22 |
| Lorazepam | 62 | $283 | $5 |
| Dilantin | 12 | $234 | $19 |
| Mirtazapine | 12 | $143 | $12 |
| Trazodone | 13 | $50 | $4 |
2013: 29 drugs
| Sabril | 40 | $364,725 | $9,118 |
| Vimpat | 129 | $135,866 | $1,053 |
| Lamictal Xr | 46 | $73,734 | $1,603 |
| Keppra | 37 | $47,609 | $1,287 |
| Felbamate | 34 | $38,198 | $1,123 |
| Topamax | 22 | $30,644 | $1,393 |
| Lamictal | 17 | $19,902 | $1,171 |
| Onfi | 43 | $19,742 | $459 |
| Lamotrigine Er | 16 | $17,797 | $1,112 |
| Lyrica | 40 | $15,690 | $392 |
| Tegretol Xr | 29 | $12,261 | $423 |
| Levetiracetam | 133 | $10,785 | $81 |
| Lamotrigine | 143 | $5,959 | $42 |
| Divalproex Sodium Er | 26 | $4,010 | $154 |
| Depakote | 12 | $3,231 | $269 |
| Gabapentin | 13 | $1,926 | $148 |
| Dilantin | 11 | $998 | $91 |
| Topiramate | 19 | $880 | $46 |
| Oxcarbazepine | 11 | $688 | $63 |
| Valproic Acid | 12 | $617 | $51 |
| Phenytoin Sodium Extended | 23 | $350 | $15 |
| Divalproex | 13 | $310 | $24 |
| Lorazepam | 34 | $219 | $6 |
| Clonazepam | 22 | $208 | $9 |
| Mirtazapine | 12 | $155 | $13 |
| Trazodone | 18 | $119 | $7 |
| Alprazolam | 13 | $105 | $8 |
| Sertraline | 11 | $96 | $9 |
| Citalopram Hbr | 12 | $71 | $6 |
Money from drug and device companies
$58,920 in 2025
| 2025 | 4 | 65 | $49,700 | $58,920 |
| 2024 | 6 | 58 | $59,500 | $69,631 |
| 2023 | 5 | 92 | $66,300 | $79,789 |
| 2022 | 5 | 92 | $88,800 | $99,959 |
| 2021 | 7 | 36 | $25,600 | $26,679 |
| 2020 | 7 | 41 | $19,275 | $21,846 |
| 2019 | 14 | 88 | $18,900 | $22,086 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| SK Life Science | Xcopri | $58,541 | 57 payments
|
| Ucb | Nayzilam | $242 | 5 payments
|
| Neuropace | Rns Neurostimulator Kit | $99 | 2 payments
|
| Neurelis | Valtoco | $38 | 1 payment
|
See all 65 published payments
| Neuropace | Travel · 2025-12-17 | Rns Neurostimulator Kit | $22 |
| SK Life Science | Meals · 2025-12-11 | Xcopri | $127 |
| SK Life Science | Honoraria · 2025-12-11 | Xcopri | $3,500 |
| SK Life Science | Honoraria · 2025-12-11 | Xcopri | $2,800 |
| Ucb | Meals · 2025-12-08 | None | $32 |
| Ucb | Meals · 2025-12-07 | None | $65 |
| SK Life Science | Meals · 2025-11-14 | None | $150 |
| SK Life Science | Meals · 2025-11-14 | None | $48 |
| SK Life Science | Travel · 2025-11-11 | Xcopri | $65 |
| SK Life Science | Travel · 2025-11-11 | Xcopri | $239 |
| SK Life Science | Honoraria · 2025-11-11 | Xcopri | $4,900 |
| SK Life Science | Travel · 2025-11-11 | Xcopri | $38 |
| SK Life Science | Honoraria · 2025-11-06 | Xcopri | $350 |
| Neurelis | Meals · 2025-11-05 | Valtoco | $38 |
| SK Life Science | Meals · 2025-10-29 | None | $27 |
| SK Life Science | Meals · 2025-10-29 | None | $9 |
| SK Life Science | Travel · 2025-10-23 | Xcopri | $547 |
| SK Life Science | Meals · 2025-10-23 | Xcopri | $124 |
| SK Life Science | Honoraria · 2025-10-23 | Xcopri | $4,900 |
| SK Life Science | Travel · 2025-10-23 | Xcopri | $276 |
| SK Life Science | Travel · 2025-10-21 | Xcopri | $766 |
| SK Life Science | Travel · 2025-09-18 | Xcopri | $835 |
| SK Life Science | Travel · 2025-09-18 | Xcopri | $716 |
| SK Life Science | Meals · 2025-09-18 | Xcopri | $125 |
| SK Life Science | Honoraria · 2025-09-18 | Xcopri | $4,900 |
| SK Life Science | Travel · 2025-09-18 | Xcopri | $230 |
| SK Life Science | Travel · 2025-08-19 | Xcopri | $185 |
| SK Life Science | Honoraria · 2025-08-19 | Xcopri | $4,200 |
| SK Life Science | Travel · 2025-08-19 | Xcopri | $338 |
| SK Life Science | Honoraria · 2025-08-18 | Xcopri | $4,200 |
| SK Life Science | Travel · 2025-08-18 | Xcopri | $338 |
| SK Life Science | Travel · 2025-08-18 | Xcopri | $185 |
| SK Life Science | Meals · 2025-08-18 | Xcopri | $120 |
| SK Life Science | Honoraria · 2025-08-18 | Xcopri | $3,500 |
| SK Life Science | Travel · 2025-08-18 | Xcopri | $338 |
| SK Life Science | Travel · 2025-08-18 | Xcopri | $185 |
| SK Life Science | Meals · 2025-08-06 | None | $150 |
| SK Life Science | Meals · 2025-08-06 | None | $44 |
| SK Life Science | Meals · 2025-07-10 | Xcopri | $125 |
| SK Life Science | Honoraria · 2025-07-10 | Xcopri | $4,900 |
| SK Life Science | Travel · 2025-07-10 | Xcopri | $542 |
| SK Life Science | Travel · 2025-07-10 | Xcopri | $198 |
| SK Life Science | Travel · 2025-07-10 | Xcopri | $199 |
| Ucb | Meals · 2025-06-05 | Fintepla | $32 |
| Ucb | Meals · 2025-06-05 | Nayzilam | $63 |
| SK Life Science | Honoraria · 2025-06-05 | Xcopri | $700 |
| Ucb | Meals · 2025-05-14 | Nayzilam | $50 |
| SK Life Science | Honoraria · 2025-05-08 | Xcopri | $700 |
| SK Life Science | Meals · 2025-04-30 | None | $22 |
| SK Life Science | Meals · 2025-04-15 | None | $4 |
| SK Life Science | Meals · 2025-04-15 | None | $2 |
| SK Life Science | Education · 2025-04-14 | Xcopri | $63 |
| SK Life Science | Meals · 2025-03-20 | Xcopri | $105 |
| SK Life Science | Honoraria · 2025-03-20 | Xcopri | $4,900 |
| SK Life Science | Travel · 2025-03-20 | Xcopri | $722 |
| SK Life Science | Travel · 2025-03-20 | Xcopri | $180 |
| SK Life Science | Travel · 2025-03-20 | Xcopri | $150 |
| SK Life Science | Honoraria · 2025-03-14 | Xcopri | $700 |
| SK Life Science | Honoraria · 2025-03-06 | Xcopri | $1,750 |
| SK Life Science | Education · 2025-03-05 | Xcopri | $63 |
| SK Life Science | Honoraria · 2025-02-25 | Xcopri | $2,800 |
| SK Life Science | Travel · 2025-02-25 | Xcopri | $40 |
| SK Life Science | Meals · 2025-02-25 | Xcopri | $108 |
| Neuropace | Meals · 2025-01-24 | Rns Neurostimulator Kit | $77 |
| SK Life Science | Meals · 2025-01-16 | None | $111 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $69,631
| SK Life Science | Xcopri | $68,501 | 52 payments
|
| Neuropace | Rns Neurostimulator Kit | $623 | 1 payment
|
| Ucb | None | $200 | 1 payment
|
| Jazz Pharmaceuticals | Epidiolex | $139 | 1 payment
|
| Catalyst Pharmaceuticals | Fycompa | $114 | 1 payment
|
| Neurelis | Valtoco | $55 | 2 payments
|
2023: $79,789
| SK Life Science | Xcopri | $79,069 | 85 payments
|
| Jazz Pharmaceuticals | Epidiolex | $320 | 3 payments
|
| Ucb | Nayzilam | $154 | 2 payments
|
| Neurelis | Valtoco | $135 | 1 payment
|
| LivaNova USA | Vns Therapy Sentiva Model 1000 Generator | $112 | 1 payment
|
2022: $99,959
| SK Life Science | Xcopri | $99,536 | 86 payments
|
| Jazz Pharmaceuticals | Epidiolex | $252 | 2 payments
|
| Ucb | Fintepla | $127 | 2 payments
|
| Medtronic | Percept PC Brainsense | $27 | 1 payment
|
| LivaNova USA | Vns Therapy Sentiva Model 1000 Generator | $18 | 1 payment
|
2021: $26,679
| SK Life Science | Xcopri | $22,300 | 23 payments
|
| Ucb | Briviact | $4,113 | 7 payments
|
| Neuropace | Rns System | $126 | 1 payment
|
| Greenwich Biosciences | Epidiolex | $63 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $42 | 2 payments
|
| Amgen | Aimovig | $21 | 1 payment
|
| LivaNova USA | Vns - Sentiva | $14 | 1 payment
|
2020: $21,846
| SK Life Science | Cenobamate | $11,664 | 17 payments
|
| Ucb | Briviact | $7,199 | 15 payments
|
| LivaNova USA | Vns Therapy | $2,323 | 5 payments
|
| Aquestive Therapeutics | Sympazan | $600 | 1 payment
|
| Sunovion Pharmaceuticals | Aptiom | $21 | 1 payment
|
| Medtronic USA | Activa | $21 | 1 payment
|
| Upsher-Smith Laboratories | Tosymra Sumatriptan Nasal Spray | $18 | 1 payment
|
2019: $22,086
| LivaNova USA | Vns Therapy | $8,545 | 26 payments
|
| Ucb | Briviact | $6,049 | 14 payments
|
| Aquestive Therapeutics | Sympazan | $3,628 | 6 payments
|
| Eisai | Fycompa | $3,233 | 9 payments
|
| Sunovion Pharmaceuticals | Aptiom | $181 | 12 payments
|
| Medtronic USA | Activa | $115 | 7 payments
|
| Greenwich Biosciences | Epidiolex | $97 | 3 payments
|
| Lilly USA | Emgality | $64 | 3 payments
|
| Amgen | Aimovig | $58 | 2 payments
|
| Bausch Health US | Migranal | $35 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $28 | 1 payment
|
| Avanir Pharmaceuticals | Nuedexta | $21 | 1 payment
|
| Novartis Pharmaceuticals | Aimovig | $20 | 1 payment
|
| Supernus Pharmaceuticals | Trokendi Xr | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| UCB SA · A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Dose Finding Study To Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal Onset Seizures in Adult · 2020 | Their institution | $26,439 |
| UCB SA · Phase II/III An Open-Label, Multicenter, Extension Study To Evaluate the Safety and Efficacy of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epileps · 2020 | Their institution | $21,275 |
| UCB SA · An Open-Label, Multicenter, Extension Study To Evaluate the Safety and Efficacy of Padsevonilas Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drugresistant Epilepsy. · 2019 | Their institution | $13,443 |
| SK Life Science, Inc. · Cenobamate · 2020 | Their institution | $9,633 |
| UCB SA · Phase II/III An Open-Label, Multicenter, Extension Study To Evaluate the Safety and Efficacy of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epileps · 2021 | Their institution | $7,134 |
| UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study To Evaluate the Efficacy and Safety of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy · 2019 | Their institution | $6,717 |
| SK Life Science, Inc. · Xcopri · 2021 | Their institution | $4,117 |
| SK Life Science, Inc. · An Open Label, Multicenter, Safety and Pharmacokinetic Study of Ykp3089 As Adjunctive Therapy in Subjects With Partial Onset Seizures · 2020 | Their institution | $875 |
| UCB SA · Phase II III An Open-Label, Multicenter, Extension Study To Evaluate the Safety and Efficacy of Padsevonil As Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epileps · 2021 | Their institution | $87 |
Professional record
- NPI
- 1861460990
- Licence
- CA G28500California G28500: Current · expires 2028-04-30
- Trained
- University of California, Irvine, California College of Medicine, 1973
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00G285000
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-03-14
- NPI last updated
- 2020-05-21
- NPI record certified
- 2020-05-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301 · 2100 Webster St #115, San Francisco, CA, 94115